TI
DFTX

Telemetry Investments’s Definium Therapeutics DFTX Stock Holding History

Telemetry Investments’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$211K Sell
96,000
-9,500
-9% -$26.4K 0.33% 70
2022
Q3 		$369K Buy
+105,500
New +$1.01M 0.47% 61

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Telemetry Investments's DFTX Position: Q4 2022 in Review

Telemetry Investments reduced its Definium Therapeutics (DFTX) stake by 9% in Q4 2022, selling an estimated $26.4K and leaving 96,000 shares worth $211K. The position accounts for 0.33% of the portfolio, ranked #70.

Telemetry Investments first reported a position in DFTX in Q3 2022 and has held it in 2 quarters since. The position peaked at $369K in Q3 2022. 104 funds tracked by Wall St. Rank hold DFTX as of Q4 2022.

  • Telemetry Investments held 96,000 shares of Definium Therapeutics worth $211K as of Q4 2022.
  • Telemetry Investments sold 9,500 Definium Therapeutics shares in Q4 2022, an estimated $26.4K.
  • Definium Therapeutics made up 0.33% of Telemetry Investments's portfolio in Q4 2022, its #70 holding.
  • Telemetry Investments first reported a position in Definium Therapeutics in Q3 2022 and has held it in 2 quarters since.
  • Telemetry Investments's Definium Therapeutics position peaked at $369K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2022.

Based on Telemetry Investments's 13F filing for Q4 2022, filed 14 Feb 2023.